Deutsch
French
Use WPMLGallagher KE
25 results
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial.Coldiron ME, Soumana I, Baudin E, Langendorf C, Mamiafo Tchoula C, Brah S, Karani A, Gallagher KE, Kagucia EW, Scott JAG, Grais RF
Lancet Infect Dis, (2025). :
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.Gallagher KE, Lucinde R, Bottomley C, Kaniu M, Suaad B, Mutahi M, Mwalekwa L, Ragab S, Twi-Yeboah L, Berkley JA, Hamaluba M, Karani A, Shangala J, Otiende M, Gardiner E, Mugo D, Smith PG, Tabu C, Were F, Goldblatt D, Scott JAG
N Engl J Med, (2024). 391:2003-2013
Factors predicting mortality in hospitalised HIV-negative children with lower-chest-wall indrawing pneumonia and implications for management.Gallagher KE, Awori JO, Knoll MD, Rhodes J, Higdon MM, Hammitt LL, Prosperi C, Baggett HC, Brooks WA, Fancourt N, Feikin DR, Howie SRC, Kotloff KL, Tapia MD, Levine OS, Madhi SA, Murdoch DR, O'Brien KL, Thea DM, Baillie VL, Ebruke BE, Kamau A, Moore DP, Mwananyanda L, Olutunde EO, Seidenberg P, Sow SO, Thamthitiwat S, Scott JAG
PLoS One, (2024). 19:e0297159
Symptom prevalence and secondary attack rate of SARS-CoV-2 in rural Kenyan households: A prospective cohort study.Gallagher KE, Nyiro J, Agoti CN, Maitha E, Nyagwange J, Karani A, Bottomley C, Murunga N, Githinji G, Mutunga M, Ochola-Oyier LI, Kombe I, Nyaguara A, Kagucia EW, Warimwe G, Agweyu A, Tsofa B, Bejon P, Scott JAG, Nokes DJ
Influenza Other Respir Viruses, (2023). 17:e13185
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.Kagucia EW, Ziraba AK, Nyagwange J, Kutima B, Kimani M, Akech D, Ng'oda M, Sigilai A, Mugo D, Karanja H, Gitonga J, Karani A, Toroitich M, Karia B, Otiende M, Njeri A, Aman R, Amoth P, Mwangangi M, Kasera K, Ng'ang'a W, Voller S, Ochola-Oyier LI, Bottomley C, Nyaguara A, Munywoki PK, Bigogo G, Maitha E, Uyoga S, Gallagher KE, Etyang AO, Barasa E, Mwangangi J, Bejon P, Adetifa IMO, Warimwe GM, Scott JAG, Agweyu A
Influenza Other Respir Viruses, (2023). 17:e13173
Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys.Gallagher KE, Adetifa IMO, Mburu C, Bottomley C, Akech D, Karani A, Pearce E, Wang Y, Kagucia EW, Goldblatt D, Hammitt LL, Scott JAG
Lancet Infect Dis, (2023). S1473-3099:00206-2
The impact of the COVID-19 pandemic on the provision & utilisation of primary health care services in Goma, Democratic Republic of the Congo, Kambia district, Sierra Leone & Masaka district, Uganda.Kasonia K, Tindanbil D, Kitonsa J, Baisley K, Zalwango F, Enria L, Mansaray A, James M, Nije Y, Tata DT, Lawal BJ, Drammeh A, Lowe B, Mukadi-Bamuleka D, Mounier-Jack S, Nakiyimba F, Obady P, Muhavi J, Bangura JS, Greenwood B, Samai M, Leigh B, Watson-Jones D, Kavunga-Membo H, Ruzagira E, Gallagher KE
PLoS One, (2023). 18:e0286295
Prevalence of IgG and IgM to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone and Uganda: A Longitudinal Study.Lawal BJ, Gallagher KE, Kitonsa J, Tindanbil D, Kasonia K, Drammeh A, Lowe B, Mukadi-Bamuleka D, Patterson C, Greenwood B, Samai M, Leigh B, Tetteh KKA, Ruzagira E, Watson-Jones D, Kavunga-Membo H
Int J Infect Dis, (2023). 131:183-192
The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.Lucinde RK, Karia B, Ouma N, Amadi D, Nyundo C, Mataza C, Nyaguara A, Scott JAG, Gallagher KE, Kagucia E
Vaccine, (2023). 41:666-675
Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21.Lucinde RK, Mugo D, Bottomley C, Karani A, Gardiner E, Aziza R, Gitonga JN, Karanja H, Nyagwange J, Tuju J, Wanjiku P, Nzomo E, Kamuri E, Thuranira K, Agunda S, Nyutu G, Etyang AO, Adetifa IMO, Kagucia E, Uyoga S, Otiende M, Otieno E, Ndwiga L, Agoti CN, Aman RA, Mwangangi M, Amoth P, Kasera K, Nyaguara A, Ng'ang'a W, Ochola LB, Namdala E, Gaunya O, Okuku R, Barasa E, Bejon P, Tsofa B, Ochola-Oyier LI, Warimwe GM, Agweyu A, Scott JAG, Gallagher KE
PLoS One, (2022). 17:e0265478
COVID-19 Vaccine Acceptability Among Healthcare Facility Workers in Sierra Leone, the Democratic Republic of Congo and Uganda: A Multi-Centre Cross-Sectional Survey.Whitworth HS, Kitonsa J, Kasonia K, Tindanbil D, Kafeero P, Bangura J, Nije Y, Tetsa Teta D, Greenwood B, Kavunga-Membo H, Leigh B, Ruzagira E, Gallagher KE, Watson-Jones D
Int J Public Health, (2022). 67:1605113
Social mixing patterns relevant to infectious diseases spread by close contact in urban Blantyre, Malawi.Thindwa D, Jambo KC, Ojal J, MacPherson P, Dennis Phiri M, Pinsent A, Khundi M, Chiume L, Gallagher KE, Heyderman RS, Corbett EL, French N, Flasche S
Epidemics, (2022). 40:100590
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Kohn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D, EBLstudy group
Lancet Infect Dis, (2022). 22:97-109
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Kohn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D, EBLstudy group
Lancet Infect Dis, (2022). 22:110-122
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya.Kagucia EW, Gitonga JN, Kalu C, Ochomo E, Ochieng B, Kuya N, Karani A, Nyagwange J, Karia B, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Ajuck H, Mukabi D, Moracha W, Bulimu D, Andanje N, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Etyang AO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG, Magarini Sub-County TDA SARS-CoV-2 Serosurveillance Team, The Busia County TDA SARS-CoV-Serosurveillance Team
Open Forum Infect Dis, (2021). 8:ofab314
Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.Lucinde RK, Ong'ayo G, Houlihan C, Bottomley C, Goldblatt D, Scott JAG, Gallagher KE
Vaccine, (2021). 39:5095-5105
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, Karanja HK, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Bottomley C, Kagucia EW, Gallagher KE, Etyang A, Voller S, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Nat Commun, (2021). 12:3966
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Science, (2021). 371:79-82
Prevalence of anti-SARS-CoV-2 IgG antibodies among Kenyan blood donors between June and August 2021..Uyoga S, Otiende M, Adetifa IMO, Karanja HK, Gitonga J, Mugo D, Makale J, Tawa B, Singilai A, Nyagwange J, Tuju J, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Kilonzo N, Chege E, Yegon C, Rotich T, Orgut I, Kagucia EW, Gallagher KE, Etyang A, Voller S, Bottomley C, Lambe T, Wright D, Tsofa B, Mwangangi J, Barasa E, Bejon P, Ochola-Oyier LI, Warimwe GM, Scott JAG, Agweyu A
1st International Conference on Public Health in Africa (CPHIA), (2021). :
High anti-SARS-CoV-2 IgG antibody seroprevalence among long-distance trucking crews in Kenya within one year of the COVID-19 pandemic..Kagucia EW, Gitonga JN, Kalu C, Kuya N, Ochieng B, Karia B, Ochomo E, Karani A, Nyagwange J, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Mukabi D, The TDA SARS-CoV-2 Serosurveillance Team, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Etyang AO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :